Public vaccination programmes against hepatitis B in The Netherlands: Assessing whether a targeted or a universal approach is appropriate

Vaccine

Volumn 28, Issue 49, 2010, Pages 7723-7730

  Houweling, Hans ^a   Wittevrongel, Christiaan F W ^a   Verweij, Marcel ^a,b   Ruitenberg, E Joost ^a,c  

^a Health Council of the Netherlands   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ATHENA INSTITUTE   (Netherlands)

Author keywords

Assessment; Hepatitis B; Public vaccination programme; Risk group approach; Selection criteria; Targeted approach; The Netherlands; Universal vaccination

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS B; HETEROSEXUALITY; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HOMOSEXUALITY; HUMAN; INTRAVENOUS DRUG ABUSE; MASS IMMUNIZATION; MEDICAL DECISION MAKING; NETHERLANDS; OCCUPATIONAL ACCIDENT; PREVALENCE; PRIORITY JOURNAL; PROSTITUTION; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SEXUAL TRANSMISSION; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS TRANSMISSION;

CHILD; DECISION MAKING; FEMALE; HEALTH POLICY; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; NATIONAL HEALTH PROGRAMS; NEEDS ASSESSMENT; NETHERLANDS; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 78349309973     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.068     Document Type: Article

References (46)

1. World Health Organization. Hepatitis B (factsheet no. 204, revised August 2008). http://www.who.int/mediacentre/factsheets/fs204/en/index.html [consulted 14.09.10].
2. Banatvala J., Van Damme P., Emiroglu N. Hepatitis B immunisation in Brita time to change?. BMJ 2006, 332(7545):804-805.
3. Pollard A.J. Hepatitis B vaccination. BMJ 2007, 335(7627):950.
4. Houweling H., Verweij M., Ruitenberg E.J. Criteria for inclusion of vaccinations in public programmes. Vaccine 2010, 28:2924-2931.
5. van Houdt R., Bruisten S.M., Koedijk F.D., Dukers N.H., Op de Coul E.L., Mostert M.C., et al. Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol 2007, 79(7):895-901.
6. Koedijk FDH, Op de Coul ELM, Cremer J, Hahné SJM, Coutinho RA, Boot H, et al. Incidentie en moleculaire epidemiologie hepatitis B virus, Nederland 2004-2007. Report nr. 210011001/2008. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu (RIVM); 2008. http://www.rivm.nl/bibliotheek/rapporten/210011001.pdf [consulted 14.09.10].
7. Okada K., Kamiyama I., Inomata M., Imai M., Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976, 294(14):746-749.
8. Beasley R.P., Trepo C., Stevens C.E., Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105(2):94-98.
9. Health Council of the Netherlands Protection against hepatitis B. Report nr. 1996/15 1996, Health Council of the Netherlands, The Hague, [in Dutch].
10. Heijnen ML, Meerburg BG, Waldhober Q, de Vries M, Hahné SJM. Landelijke hepatitis B-vaccinatiecampagne voor gedragsgebonden risicogroepen: resultaten en veranderingen. Bilthoven: RIVM; 2007. http://www.rivm.nl/infectieziektenbulletin/bul1811/art_hepb.html [consulted 14.09.10].
11. Health Council of the Netherlands Universal vaccination against hepatitis B. Report nr. 2001/03 2001, Health Council of the Netherlands, The Hague, [in Dutch].
12. Grosheide P.M., den Ouden A.L., Verrips G.H., Conyn-van Spaendonck M.A., Loeber J.G., Verloove-Vanhorick S.P. Evaluation of the hepatitis B prevention program in newborn infants. I. National data, 1990. Ned Tijdschr Geneeskd 1993, 137(50):2589-2594. [in Dutch].
13. Vogels T., van der Ploeg C.P.B., Schuller A.A., Vogelaar J.A., Verkerk P.H. Procesevalatie pre- en postnatale screeningen,eerste fase. TNO report nr. 2001.201 2001, TNO preventie en gezondheid, Leiden.
14. Health Council of the Netherlands Vaccination of children against hepatitis B. Publication nr. 2003/14 2003, Health Council of the Netherlands, The Hague, [in Dutch].
15. van Lier EA, van Oomen PJ, Oostenbrug MWM, Zwakhals SLN, Drijfhout IH, de Hoogh PAAM, et al. Vaccinatiegraad Rijksvaccinatieprogramma Nederland; verslagjaar 2006-2008. [Immunization coverage National Immunization Programme in the Netherlands, year of report 2006-2008] Report nr. 210021007/2008. Bilthoven: RIVM; 2008: 210021007/2008. http://www.rivm.nl/bibliotheek/rapporten/210021007.html [consulted 14.09.10].
16. De Wit GA, Busch MCM. Preventie van hepatitis B kort en bondig. In: Nationaal Kompas Volksgezondheid. Bilthoven: National Institute of Public Health and Environmental Protection (RIVM); 2006. http://www.nationaalkompas.nl/preventie/van-ziekten-en-aandoeningen/infectieziekten/hepatitis-b/preventie-van-hepatitis-b-samengevat/ [consulted 14.09.10].
17. Health Council of the Netherlands. The future of the National Immunisation Programme: towards a programme for all age groups. Report nr. 2007/02E. The Hague: Health Council of the Netherlands; 2007. http://www.gezondheidsraad.nl/en/publications/future-national-immunisation-programme-towards-programme-all-age-groups [consulted 14.09.10].
18. Kretzschmar M., Mangen M.J., van de Laar M., de Wit A. Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 2009, 27(8):1254-1260.
19. Hontelez J.A., Hahné S., Koedijk F.H., de Melker H.E. Effectiveness and impact of HBV vaccination of children with at least one parent born in an HBV endemic country: an early assessment. J Epidemiol Community Health 2009.
20. van Houdt R., Koedijk F.D., Bruisten S.M., Coul E.L., Heijnen M.L., Waldhober Q., et al. Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: does it work?. Vaccine 2009, 27(27):3530-3535.
21. van Houdt R., Sonder G.J., Dukers N.H., Bovee L.P., van den Hoek A., Coutinho R.A., et al. Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlands. Vaccine 2007, 25(14):2698-2705.
22. van Ballegooijen W.M., van Houdt R., Bruisten S.M., Boot H.J., Coutinho R.A., Wallinga J. Molecular sequence data of hepatitis B virus and genetic diversity after vaccination. Am J Epidemiol 2009, 170(12):1455-1463.
23. Xiridou M., Wallinga J., Dukers-Muijers N., Coutinho R. Hepatitis B vaccination and changes in sexual risk behaviour among men who have sex with men in Amsterdam. Epidemiol Infect 2008, 1-9.
24. Health Council of the Netherlands. General vaccination against hepatitis B revisited. Report 2009/03E. The Hague: Health Council of the Netherlands; 2009. http://www.gezondheidsraad.nl/en/publications/general-vaccination-against-hepatitis-b-revisited [consulted 14.09.10].
25. De Wit G.A., Kretzschmar M.E.E., Smits L.J.M., Struijs J.N., Postma M.J., van de Laar M.J.W., et al. Kosteneffectiviteit van algemene vaccinatie tegen hepatitis B (interimrapportage). Report nr. 403505004 2000, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven.
26. Kretzschmar M., De Wit G.A., Smits L.J., van de Laar M.J. Vaccination against hepatitis B in low endemic countries. Epidemiol Infect 2002, 128(2):229-244.
27. Mast E., Mahoney F., Kane M., Margolis H. Hepatitis B vaccine. Vaccines 2004, 299-337. Saunders, Philadelphia. S.A. Plotkin, W.A. Orenstein (Eds.).
28. Chien Y.C., Jan C.F., Kuo H.S., Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006, 28:126-135.
29. Bonanni P., Pesavento G., Bechini A., Tiscione E., Mannelli F., Benucci C., et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003, 21(7-8):685-691.
30. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-125.
31. Avdicova M., Prikazsky V., Hudeckova H., Schuerman L., Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 months vaccination schedule. Eur J Pediatr 2002, 161(11):581-587.
32. Cheng H.K., Rajadurai V.S., Amin Z., Sriram B., Yee M.F., Han H.H., et al. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine. Southeast Asian J Trop Med Public Health 2004, 35(3):685-692.
33. Zepp F., Knuf M., Heininger U., Jahn K., Collard A., Habermehl P., et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004, 22(17-18):2226-2233.
34. Tichmann I., Preidel H., Grunert D., Habash S., Schult R., Maier R., et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005, 23(25):3272-3279.
35. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006, 78(2):169-177.
36. Heininger U., Sanger R., Jacquet J.M., Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007, 25(6):1055-1063.
37. Hernán M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004, 63(5):838-842.
38. World Health Organization. World Health Organization Global Advisory Committee on Vaccine Safety. Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled " Recombinant hepatitis B vaccine and the risk of multiple sclerosis" 2004. http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/ [consulted 14.09.10].
39. Health Council of the Netherlands. Hepatitis B vaccination and multiple sclerosis. In: Health Council of the Netherlands (Ed.), General vaccination against hepatitis B revisited (Appendix C). Report 2009/03E. The Hague: Health Council of the Netherlands; 2009. http://www.gezondheidsraad.nl/en/publications/general-vaccination-against-hepatitis-b-revisited [consulted 14.09.10].
40. Jefferson T, Di Pietrantonj C, Rivetti A, Demicheli V. Hepatitis B (HB) immunization and onset of demyelinating disease: systematic review of the evidence. In: General vaccination against hepatitis B revisited (Appendix D). Report 2009/03E. The Hague: Health Council of the Netherlands; 2009. http://www.gezondheidsraad.nl/en/publications/general-vaccination-against-hepatitis-b-revisited [consulted 14.09.10].
41. Health Council of the Netherlands. Vaccination against cervical cancer. Report nr. 2008/08E. The Hague: Health Council of the Netherlands; 2008. http://www.gezondheidsraad.nl/en/publications/vaccination-against-cervical-cancer-0 [consulted 14.09.10].
42. de Melker H., Berbers G., Hahné S., Rumke H., van den H.S., De Wit A., et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006, 24(18):3946-3952.
43. de Melker HE, Gerritsen AAM, Hahné SJM. The national immunization programme in the Netherlands, developments in 2006. Report nr. 210021006/2007. Bilthoven: RIVM; 2007. http://www.rivm.nl/bibliotheek/rapporten/210021006 [consulted 14.09.10].
44. Mangen M.J., van Duynhoven Y.T.H.P., Vennema H., van Pelt W., Havelaar A.H., de Melker H.E. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28:2624-2635.
45. Hontelez J.A., Hahné S.J., Oomen P., de Melker H. Parental attitude towards childhood HBV vaccination in The Netherlands. Vaccine 2010, 28(4):1015-1020.
46. Klink A. Algemene vaccinatie tegen hepatitis B in het Rijksvaccinatieprogramma (letter of the Minister of Health to the Second Chamber of parliament). The Hague: Ministry of Health, Social Welfare and Sports (VWS); 2010. http://www.rijksoverheid.nl/ministeries/vws/documenten-en-publicaties/kamerstukken/2010/07/22/algemene-vaccinatie-tegen-hepatitis-b-in-het-rijksvaccinatieprogramma.html [consulted 14.09.10].